Revive Therapeutics Announces FDA Grants Orphan Drug Designation for Cannabidiol in the Treatment of Autoimmune Hepatitis

TORONTO, June 27, 2018 -- (Healthcare Sales &Marketing Network) -- Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) (FSE:31R) ("Revive" or the "Company"), a company focused on the research, development and commercialization of ... Biopharmaceuticals, FDA Revive Therapeutics, cannabinoid, autoimmune hepatitis, hepatitis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Badawy AA, El-Rabat A, Elshazly TA, Ali SA, Alruwaili AM, Gad DF, Dawoud MG, Elmasry EE, Zaki ME PMID: 31109254 [PubMed - as supplied by publisher]
Source: British Journal of Biomedical Science - Category: Laboratory Medicine Tags: Br J Biomed Sci Source Type: research
Investigation of the clinical significance and prospective molecular mechanisms of cystatin genes in patients with hepatitis B virus‑related hepatocellular carcinoma. Oncol Rep. 2019 May 09;: Authors: Zhou X, Wang X, Huang K, Liao X, Yang C, Yu T, Liu J, Han C, Zhu G, Su H, Qin W, Han Q, Liu Z, Huang J, Gong Y, Ye X, Peng T Abstract The present study aimed to investigate the clinical significance and prospective molecular mechanism of cystatin (CST) genes in patients with hepatitis B virus (HBV)‑related hepatocellular carcinoma (HCC). The role of CST genes in the molecular mechanism of HCC was reve...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
This study investigated whether NGF prevents tumor growth by promoting neuronal regulation of tumor blood flow. HT1080 fibrosarcoma cells or HepG2 hepatitis cells were subcutaneously implanted into nude mice. On Day 21 after the implantation of tumor cells, human NGF (40 or 80 ng/h for 14 days) was administered using a micro-osmotic pump. Growth rates of both tumors were significantly inhibited by the treatment of NGF, and the survival rate was also extended. Significant suppression of HT1080 tumor growth lasted after withdrawing NGF. NGF markedly increased the density of α-smooth muscle actin (α-SMA)-immunorea...
Source: Journal of Pharmacological Sciences - Category: Drugs & Pharmacology Source Type: research
A 9‑lncRNA risk score system for predicting the prognosis of patients with hepatitis B virus‑positive hepatocellular carcinoma. Mol Med Rep. 2019 May 22;: Authors: Liu H, Zhao P, Jin X, Zhao Y, Chen Y, Yan T, Wang J, Wu L, Sun Y Abstract Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, and can be induced by hepatitis B virus (HBV) infection. The aim of the present study was to screen prognosis‑associated long noncoding RNAs (lncRNAs) and construct a risk score system for the disease. The RNA‑sequencing data of patients with HCC (including 100 HCC samples...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
Conditions:   Beta-Thalassemia;   Hepatitis C Intervention:   Drug: Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni] Sponsor:   Tanta University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Kishore and colleagues in NEJM, including Josiah Rich from a university well known to me, discuss the harm reduction approach to injection drug use (IDU). Basically, this means using evidence to guide practice so as to minimize as much as possible the adverse public health consequences of addiction. In addition to the risk of overdose, which is getting most of the attention nowadays, IDU is a means of transmission of Hepatitis C and HIV, and contaminated needles transmit other common infectious organisms that can result in abscesses, and very serious consequences such as myocarditis.So, assuring that users have access to s...
Source: Stayin' Alive - Category: American Health Source Type: blogs
CONCLUSIONS: Hepatitis C/HIV co-infection among GBM cannot be understood in isolation from co-occurring drug use and sex, nor as separate from their HIV infection. Hepatitis C prevention must address subcultural heterogeneity and the intersectionality between multiple stigmatized social identities. Hepatitis C care presents an opportunity to provide support beyond cure. Peer support networks could mitigate social capital loss following a commitment to behaviour change and reduce hepatitis C reinfection risks. PMID: 31111671 [PubMed - in process]
Source: Journal of the International AIDS Society - Category: Infectious Diseases Tags: J Int AIDS Soc Source Type: research
Publication date: August 2019Source: Journal of Functional Foods, Volume 59Author(s): Bernadetta Lis, Beata OlasAbstractSince ancient times, dandelion (Taraxacum officinale L.) has been consumed in various forms as a valuable source of nutrients, minerals and vitamins which can also have beneficial effects on various complex diseases. It is described as a nontoxic herb with exceptional biological activity. The aim of this review is to present the multidirectional activity of various dandelion products whose dietary intake may help to prevent, or reduce the risk of, the development of a range of diseases, including cancer, ...
Source: Journal of Functional Foods - Category: Nutrition Source Type: research
Authors: Otero MÁ, Liu CH, Ampuero J, Llorca R, Vargas M, Vargas-Romero J, Romero-Gómez M Abstract INTRODUCTION AND AIM: The detection of hepatitis B virus (HBV) depends on primary care center activity. The present study aims to investigate the impact of peer-to-peer sessions with hepatologists on hepatitis B screening efficacy in primary care centers. MATERIAL AND METHODS: Peer-to-peer one-hour sessions were scheduled to improve the screening program for HBV in Seville, Spain. The sessions were focused on who should be tested for HBV and how positive cases should be referred. Fourteen out of 26 h...
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
CONCLUSIONS: Treatment with LDV/SOF with/without RBV for 12-24 weeks was very well tolerated and resulted in high SVR 12 rates (96%) in HCV GT1 relapsers to SMV + SOF treatment. PMID: 31104796 [PubMed - in process]
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
More News: Grants | Hepatitis | Marketing | Pharmaceuticals